2026 BD opportunity scan for Feldan Bio, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Dren Bio, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Daiichi Sankyo Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Chia Tai Tianqing Pharmaceutical Group Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals an

2026 BD opportunity scan for Changchun Genescience Pharmaceuticals Co., Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and

2026 BD opportunity scan for Blueprint Medicines Corp.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Asahi Kasei Corp.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Kind Pharmaceuticals LLC: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Kimera Labs, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Karuna Therapeutics, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for Kallyope, Inc.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach rationale.

2026 BD opportunity scan for JYAMS PET Research & Development Ltd.: pipeline stage, evidence package, IP risk, deal precedent, financial signals and outreach